Evidence map›Paper›PMID 33230879›Full record

ArticleEuropean journal of haematology2021

Characterization and prognostic implication of delayed complete response in AL amyloidosis.

Eli Muchtar, Morie A Gertz, Shaji K Kumar, Martha Q Lacy, Nelson Leung, Francis K Buadi, David Dingli, Suzanne R Hayman, Ronald S Go, Prashant Kapoor and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Eli MuchtarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID https://orcid.org/0000-0003-2210-2174
Morie A GertzDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Shaji K KumarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Martha Q LacyDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Nelson LeungDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Francis K BuadiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
David DingliDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Suzanne R HaymanDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Ronald S GoDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Prashant KapoorDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Wilson GonsalvesDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID https://orcid.org/0000-0001-6890-969X
Taxiarchis V KourelisDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Rahma WarsameDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Yi Lisa HwaDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID https://orcid.org/0000-0002-8163-2979
Amie FonderDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Miriam HobbsDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Stephen RussellDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
John A LustDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Mustaqueem SiddiquiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
S Vincent RajkumarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Robert A KyleDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Angela DispenzieriDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID https://orcid.org/0000-0001-8780-9512

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5M
Henry J. Predolin FoundationJabbs FoundationNCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

introductionLittle is known on continued response following completion of therapy in light chain (AL) amyloidosis.

methodsWe studied 373 AL amyloidosis patients who achieved complete response (CR) or very good partial response (VGPR) to first-line therapy.

resultsBy end of therapy (EOT), 46% of patients achieved a CR and 54% a VGPR. With no further therapy, 17.5% of patients were upstaged from VGPR to CR (delayed CR), with a median of 9 months. Compared with CR and VGPR at EOT, patients with a delayed CR were characterized by higher proportion of t(11;14) and lower rate of trisomies. Autologous stem cell transplant was more frequent in the delayed CR group. Patients with a delayed CR were characterized by minimal residual disease negativity and organ response rates similar to patients with CR at EOT and higher than patients achieving VGPR at EOT. Patients with a delayed CR had a longer PFS/OS compared to patients with CR or VGPR by EOT (median PFS 149 vs 92 vs 52 months, P < .001; 10-year OS 87% vs 71% vs 56%, P < .001).

conclusionsThis study characterizes delayed CR in AL amyloidosis, highlights its prognostic impact which is at least similar to those who achieved CR at EOT, and underlines another aspect of response monitoring.

Indexed as

Combined Modality TherapyDisease ManagementHumansImmunoglobulin Light-chain AmyloidosisOutcome Assessment, Health CarePrognosisTime FactorsTreatment Outcomeautologous stem cell transplantimmunoparesisoff-therapysurvival

Identifiers

PMID33230879
PMCPMC8103541

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.